Physiomics PLC Awarded two further contracts by Bicycle
March 03 2020 - 2:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
03 March 2020
3 March 2020
Physiomics plc
("Physiomics") or (the "Company")
Physiomics awarded two further contracts by Bicycle
Therapeutics
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions, is pleased to announce that it has
been awarded two further contracts of undisclosed value with its
existing client Bicycle Therapeutics ("Bicycle"), building on the
two projects announced in 2019.
Last year Physiomics worked with Bicycle on BT1718, its lead
programme currently in a Cancer Research UK-sponsored Phase I/IIa
clinical in solid tumours. Physiomics' role related to the analysis
of clinical data from this trial, and the Company's work was
acknowledged in a poster presentation at the ESMO conference in
September 2019(1) . Separately, Physiomics also worked with Bicycle
on the mathematical modelling of interactions between tumour and
Bicycle compounds in an immune-oncology setting, which at the time
of its announcement was the fourth project conducted by Physiomics
in the immune-oncology space.
The projects announced today will involve pharmacokinetic and
pharmacodynamic analysis of a number of Bicycle compounds and build
on work completed by the Company previously. Both projects are
expected to be completed in the next six months.
Dr Jim Millen, CEO said : "We are delighted to be working with
Bicycle Therapeutics again in 2020 and believe that we are
contributing significantly to key development decisions. It is
particularly interesting to be working with Bicycle at a time when
it is forging close relationships with large cap pharma companies
as evidenced by the recent announcement of a significant new deal
with US giant Genentech(2) "
(1)https://www.bicycletherapeutics.com/wp-content/uploads/ESMO-Sep-2019-FINAL.pdf
(2)https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-exclusive-strategic-collaboration
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry. The Company's Virtual Tumour(TM) technology
uses computer modelling to predict the effects of cancer drugs and
treatments to improve the success rate of drug discovery and
development projects while reducing time and cost. The predictive
capability of Physiomics' technologies have been confirmed by over
70 projects, involving over 30 targets and 60 drugs, and has worked
with clients such as Merck KGaA, Merck & Co, Bayer and
Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFLFVRVFIFIII
(END) Dow Jones Newswires
March 03, 2020 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024